Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta‐analysis

Physicians are sometimes reluctant to initiate guideline‐directed therapy in patients with heart failure and reduced ejection fraction (HFrEF) due to concerns of adverse events. We explored the risk of hypotension, volume depletion, and acute kidney injury (AKI) on sodium–glucose cotransporter 2 (SGLT2) inhibitors in HFrEF populations.

[1]  L. Lund,et al.  ‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor , 2021, ESC heart failure.

[2]  P. Ponikowski,et al.  Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. , 2021, Journal of the American College of Cardiology.

[3]  R. McKelvie,et al.  CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. , 2021, The Canadian journal of cardiology.

[4]  S. Kaul,et al.  Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. , 2020, Circulation.

[5]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[6]  J. McMurray,et al.  Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) , 2020, Circulation.

[7]  G. Filippatos,et al.  Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction , 2020, Circulation.

[8]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[9]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[10]  D. DeMets,et al.  Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) , 2020, European heart journal.

[11]  D. DeMets,et al.  Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF , 2020, Circulation.

[12]  B. Zinman,et al.  Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. , 2020, Journal of hypertension.

[13]  A. Levin,et al.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.

[14]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[15]  M. Drazner,et al.  Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. , 2019, Circulation.

[16]  Isabelle Boutron,et al.  The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses. , 2019, Journal of clinical epidemiology.

[17]  Akshay S. Desai,et al.  Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial , 2019, European journal of heart failure.

[18]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[19]  M. Cho,et al.  Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. , 2017, JACC. Heart failure.

[20]  A. Kengne,et al.  Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients , 2017, Journal of the American Heart Association.

[21]  S. Solomon,et al.  Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF , 2017, European heart journal.

[22]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[23]  M. Vaduganathan,et al.  The vulnerable phase after hospitalization for heart failure , 2015, Nature Reviews Cardiology.

[24]  J. Coresh,et al.  GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  I. Tikkanen,et al.  Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.

[26]  C. O'connor,et al.  Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. , 2014, European heart journal.

[27]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[28]  M. Gheorghiade,et al.  The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. , 2011, American heart journal.

[29]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.